DE69417049D1 - Hydroxamsäurederivate als inhibitoren von cylokine produktion - Google Patents

Hydroxamsäurederivate als inhibitoren von cylokine produktion

Info

Publication number
DE69417049D1
DE69417049D1 DE69417049T DE69417049T DE69417049D1 DE 69417049 D1 DE69417049 D1 DE 69417049D1 DE 69417049 T DE69417049 T DE 69417049T DE 69417049 T DE69417049 T DE 69417049T DE 69417049 D1 DE69417049 D1 DE 69417049D1
Authority
DE
Germany
Prior art keywords
pct
side chain
alkyl
group
polar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69417049T
Other languages
English (en)
Other versions
DE69417049T2 (de
Inventor
Michael Crimmin
Paul Beckett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Publication of DE69417049D1 publication Critical patent/DE69417049D1/de
Application granted granted Critical
Publication of DE69417049T2 publication Critical patent/DE69417049T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Indole Compounds (AREA)
DE69417049T 1993-10-07 1994-10-04 Hydroxamsäurederivate als inhibitoren von cylokine produktion Expired - Fee Related DE69417049T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939320660A GB9320660D0 (en) 1993-10-07 1993-10-07 Inhibition of cytokine production
PCT/GB1994/002145 WO1995009841A1 (en) 1993-10-07 1994-10-04 Hydroxamic acid derivatives as inhibitors of cytokine production

Publications (2)

Publication Number Publication Date
DE69417049D1 true DE69417049D1 (de) 1999-04-15
DE69417049T2 DE69417049T2 (de) 1999-09-16

Family

ID=10743152

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69417049T Expired - Fee Related DE69417049T2 (de) 1993-10-07 1994-10-04 Hydroxamsäurederivate als inhibitoren von cylokine produktion

Country Status (9)

Country Link
US (1) US5821262A (de)
EP (1) EP0722438B1 (de)
JP (1) JPH09503222A (de)
AT (1) ATE177422T1 (de)
AU (1) AU7787594A (de)
DE (1) DE69417049T2 (de)
GB (1) GB9320660D0 (de)
WO (1) WO1995009841A1 (de)
ZA (1) ZA947799B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
WO1996033991A1 (en) * 1995-04-26 1996-10-31 Sankyo Company, Limited β-NONYLHYDROXAMIC ACID DERIVATIVES
JPH11504934A (ja) * 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
US6281352B1 (en) 1995-11-14 2001-08-28 Dupont Pharmaceuticals Company Macrocyclic compounds as metalloprotease inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
CZ292617B6 (cs) 1995-11-23 2003-11-12 British Biotech Pharmaceuticals Limited Inhibitory metaloproteinázy a farmaceutický prostředek
DE69624081T2 (de) * 1995-12-20 2003-06-12 Hoffmann La Roche Matrix-metalloprotease Inhibitoren
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
EP1005343A1 (de) * 1996-03-08 2000-06-07 Smithkline Beecham Corporation Verwendung von csaids als inhibitoren der angiogenese
AU2645497A (en) * 1996-05-06 1997-11-26 Zeneca Limited Thio derivatives of hydroxamic acids
PT1021424E (pt) * 1996-06-21 2003-06-30 Upjohn Co Amidas de tiadiazolo como inibidores da metaloproteinase de matriz
EP0818442A3 (de) * 1996-07-12 1998-12-30 Pfizer Inc. Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
CA2265666C (en) 1996-09-10 2008-01-15 British Biotech Pharmaceuticals Limited Cytostatic hydroxamic acid derivatives
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
DE69732571T2 (de) * 1996-09-27 2006-01-12 Pharmacia & Upjohn Co., Kalamazoo Beta-sulfonyl-hydroxamsäuren als matrix-metalloproteinaseinhibitoren
GB9625895D0 (en) * 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
EP0960096B1 (de) * 1997-01-22 2005-04-06 Aventis Pharmaceuticals Inc. Substituierte beta-thiocarbonsäuren
AU5493598A (en) * 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DK0973392T3 (da) * 1997-03-04 2004-03-29 Monsanto Co Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser
US5847148A (en) * 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
US6300514B1 (en) 1997-06-25 2001-10-09 Ono Pharmaceutical Co., Ltd. Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
HRP980443A2 (en) 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
WO1999025687A1 (en) 1997-11-14 1999-05-27 G.D. Searle & Co. Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP3621884B2 (ja) 1998-01-09 2005-02-16 ファイザー・インク マトリックスメタロプロテアーゼ阻害剤
WO1999041246A1 (en) 1998-02-11 1999-08-19 Du Pont Pharmaceuticals Company Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
GEP20043238B (en) 1999-02-08 2004-05-25 Searle & Co Sulfamato Hydroxamic Acid Metalloprotease Inhibitor, its Use in Preparation of Pharmaceutical Composition for Treatment of Conditions Associated with Pathological Matrix Metalloprotease Activity
AU4181000A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU4180900A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
EP1712239A3 (de) * 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 Inhibitoren zur Behandlung von Erkrankungen
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
PL367487A1 (en) 2001-05-11 2005-02-21 Pharmacia Corporation Aromatic sulfone hydroxamates and their use as protease inhibitors
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7119203B2 (en) 2002-04-25 2006-10-10 Pharmacia Corporation Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
EP1610678B1 (de) 2003-04-04 2011-07-27 Yeda Research And Development Co., Ltd. Antikörper zur hemmung der aktivität von mmp-2 und mmp-9
EP1626961B1 (de) 2003-05-17 2011-11-02 Korea Research Institute of Bioscience and Biotechnology Neue heterozyklische 2-oxo-verbindungen und pharmazeutische zusammensetzungen, die diese enthalten
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1653952A4 (de) * 2003-08-06 2007-04-04 Pfizer Prod Inc Oxazol-verbindungen zur behandlung von neurodegenerativen störungen
WO2005014825A2 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US7914771B2 (en) 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
JPWO2006016399A1 (ja) 2004-08-10 2008-05-01 株式会社静岡カフェイン工業所 ヒドロキサム酸誘導体及びそれを有効成分とする医薬
US7879997B2 (en) 2005-08-12 2011-02-01 Schering Corporation Compounds for the treatment of inflammatory disorders
MX2009008914A (es) 2007-02-23 2009-08-28 Yeda Res & Dev Anticuerpos y composiciones farmaceuticas que contienen los mismos, utiles para inhibir la actividad de metaloproteinas.
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
JPH05503720A (ja) * 1990-12-03 1993-06-17 セルテック　リミテッド ペプチジル誘導体
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9220845D0 (en) * 1992-10-03 1992-11-18 British Bio Technology Vasoactive peptide inhibition
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production

Also Published As

Publication number Publication date
EP0722438B1 (de) 1999-03-10
EP0722438A1 (de) 1996-07-24
AU7787594A (en) 1995-05-01
JPH09503222A (ja) 1997-03-31
US5821262A (en) 1998-10-13
ZA947799B (en) 1995-07-10
GB9320660D0 (en) 1993-11-24
DE69417049T2 (de) 1999-09-16
ATE177422T1 (de) 1999-03-15
WO1995009841A1 (en) 1995-04-13

Similar Documents

Publication Publication Date Title
ATE177422T1 (de) Hydroxamsäurederivate als inhibitoren von cylokine produktion
SE8001099L (sv) Beta-laktamforeningar
KR910019612A (ko) 옥살릴아미노산 유도체, 이의 제조방법 및 프롤린 하이드록실라제 억제용 약제로서의 이의 용도
DE69512797T2 (de) Prostaglandin-synthase hemmer
DK0554543T3 (da) 1,2,4-triaminobenzenderivater og fremgangsmåde til deres fremstilling
KR830009107A (ko) 2-페넴 화합물의 제조방법
DE69505542T2 (de) 3-benzoylbenzofuran-derivate als thyroidhormonantagonisten
EA199800091A1 (ru) Аминосилановые соли и силаноамиды карбоновых кислот как ингибиторы коррозии
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
ES8200645A1 (es) Un procedimiento para la preparacion de un muramildipeptido.
FI943931A0 (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiittoreina
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
ATE209205T1 (de) Indan-2-mercaptoacetylamid disulfidderivate als enkephalinase inhibitoren
DE69810651D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
DE69808326D1 (de) Azetidinonderivate zur behandlung von hcmv entzündungen
NZ337221A (en) Imino-aza-anthracyclinone derivatives for the treatment of amyloidosis
AU9035491A (en) Chiral hydantoin resolution
FR3077201B1 (fr) Derives aminoacides contenant un groupement disulfanyle sous forme d'un inhibiteur de nep et d'apn pour la prevention et le traitement des douleurs relatives au nerf trijumeau
NO981051L (no) Peptidderivater
EP1057829A4 (de) Kondensierte Pyrimidinderivate und diese enthaltende pharmazeutische Zubereitungen
DE3368923D1 (en) Acid derivatives, method for their preparation and their use in combating microorganisms
PL307851A1 (en) 4-keto azetidine sulphonic-2 amides and their salts, method of obtaining them and their application
DK0823254T3 (da) Hidtil ukendt anvendelse af pyrazolopyridinforbindelser
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee